Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

ll as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

MEDAREX, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

Year Ended Three Months Ended

December 31, December 31,

(unaudited)

2007 2006 2007 2006

Contract and license

revenues $35,906 $28,289 $15,135 $6,769

Reimbursement of

developments costs 20,352 20,357 5,362 4,557

Total revenues 56,258 48,646 20,497 11,326

Costs and expenses:

Research and development 198,317 194,512 56,857 52,187

General and administrative 46,925 51,928 11,905 16,801

Acquisition of in-process

technology 6,900 - - -

Operating loss (195,884) (197,794) (48,265) (7,662)

Equity in net loss of

affiliate - (1,037) - -

Interest income, net
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... 2014 The finalists are in for ... industry trade magazine, will honor the pharmaceutical industry’s most ... given to outstanding companies, marketers and brand managers representing ... “We are proud to announce that we received our ... double the number of submissions we received last year,” ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2
... Dec. 20 HMS Holdings Corp. (Nasdaq:,HMSY) today announced ... Conference, which will be held January 7-10, 2008 at ... http://www.newscom.com/cgi-bin/prnh/20030304/NYTU172LOGO ), Robert Holster, Chairman and CEO ... at 2:00 p.m. Pacific Time., A live broadcast ...
... to determine if treating depression improves health of ... heart ... with heart,disease are more likely to suffer from depression than those ... well understood,but it is known that depression in heart patients is ...
... THURSDAY, Dec. 20 (HealthDay News) -- Exposure to secondhand ... of developing allergies, Swedish researchers say. , A team ... by the parents of more than 4,000 families. , ... were ages two months, 12 months, 2 years and ...
... Toronto Stock Exchange Symbol: AKL, MONTREAL, Dec. ... drug development company focused on developing therapies for ... to unfavorable market,conditions, particularly in the small and ... public offering initiative. The Company is currently,contemplating other ...
... University researchers have updated their Food Guide Pyramid for ... now known as MyPyramid. The Tufts version is specifically ... and content. The Modified MyPyramid for Older Adults continues ... fluid balance, but has added additional guidance about forms ...
... WESTBROOK, Maine, Dec. 19 IDEXX Laboratories,Inc. (Nasdaq: ... the,JPMorgan 26th Annual Healthcare Conference. Jonathan W. Ayers, Chairman,President ... the Company on,Monday, January 7, 2008 at 8:00 a.m. ... Individuals can access the live audio webcast of,the presentation ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2Health News:Akela Pharma provides corporate update 2Health News:Tufts researchers update their food guide pyramid for older adults 2Health News:Tufts researchers update their food guide pyramid for older adults 3
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... announced last Thursday, August 14, 2014, has closed.  The ... convertible at $7.30 per share of common stock.  The ... to purchase up to an additional 30% of these ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Inquire...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Medicine Products: